Sanofi out­lines big API plans as coro­n­avirus out­break re­port­ed­ly threat­ens short­age of 150 drugs

As the world be­comes in­creas­ing­ly de­pen­dant on Asia for the in­gre­di­ents of its med­i­cines, Sanofi sees busi­ness to be done in Eu­rope.

The French drug­mak­er said it’s cre­at­ing the world’s sec­ond largest ac­tive phar­ma­ceu­ti­cal in­gre­di­ents (API) man­u­fac­tur­er by spin­ning out its six cur­rent sites in­to a stand­alone com­pa­ny: Brin­disi (Italy), Frank­furt Chem­istry (Ger­many), Haver­hill (UK), St Aubin les El­beuf (France), Újpest (Hun­gary) and Ver­to­laye (France). They have mapped out €1 bil­lion in ex­pect­ed sales by 2022 and 3,100 em­ploy­ees for the new op­er­a­tions head­quar­tered in France.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.